Latest news

• Biocon backs away from biosimilar filings in Europe

  white cell booster Neulasta (pegfilgrastim) at the request of the EMA.

• Novartis says its biosimilar sales should reach $1bn this year

  The biosimilar is also under review in Europe. Meanwhile, Novartis confirmed that it will have to carry out a new clinical trial on its biosimilar version of Amgen's Neulasta (pegfilgrastim),

• Novartis gets FDA panel backing for biosimilar Enbrel

  The company has several other biosimilars in clinical development, including copycat versions of Humira, Roche's MabThera/Rituxan (rituximab), Amgen's Epogen (epoetin alfa) and Neulasta (pegfilgrastim) and Johnson &Johnson's

• Sandoz files for approval of Neulasta biosimilar in Europe

  The European Medicines Agency (EMA) has now started its review of the Neulasta (pegfilgrastim) biosimilar - a long-acting granulocyte colony-stimulating factor (GCSF) that is used to prevent low white cell

• FDA accepts Sandoz filing for biosimilar Neulasta

  Neulasta (pegfilgrastim) is a long-acting granulocyte colony stimulating factor (G-CSF) that is used to bolster white cells in patients undergoing chemotherapy for cancer, and remains one of Amgen's